Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Articles published in Journal of Multiple Sclerosis have been cited by esteemed scholars and scientists all around the world. Journal of Multiple Sclerosis has got h-index 11, which means every article in Journal of Multiple Sclerosis has got 11 average citations.
Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
55 | 59 | 6 | 3 | 9 |
Year wise citations received |
54 | 59 | 46 | 57 | 43 |
| Journal total citations count | 521 |
| Journal Impact Factor | 2.30 |
| Journal 5 years Impact Factor | 2.28 |
| Journal CiteScore | 1.96 |
| Journal h-index | 11 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal CiteScore |
| CiteScorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Breward, N. J. (2019). A Systematic Review Examining Cannabis Use for the Treatment of Multiple Sclerosis (Doctoral dissertation, University of Saskatchewan). |
|
Alessandria, G., Meli, R., Infante, M. T., Vestito, L., Capello, E., & Bandini, F. (2020). Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study. Clinical Neurology and Neurosurgery, 196, 105990. |
|
Nischala, T. (2016). Multiple sclerosis patients gets the most help from Nurses. J Nurs Health Sci| Volume, 2(3). |
|
Amato, L., Minozzi, S., Mitrova, Z., Parmelli, E., Saulle, R., Cruciani, F., ... & Davoli, M. (2017). Revisione sistematica sull’efficacia terapeutica e la sicurezza della cannabis per i pazienti affetti da sclerosi multipla, dolore neuropatico cronico e pazienti oncologici che assumono chemioterapie. Epidemiol Prev, 41(5-6), 279-293. |
|
Prieto Gonzalez, J. M., & Vila Silvan, C. (2021). Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports. Expert Review of Neurotherapeutics, 21(5), 547-558. |
|
Prieto Gonzalez, J. M., & Vila Silvan, C. (2021). Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports. Expert Review of Neurotherapeutics, 21(5), 547-558. |
|
Marková, J. (2019). Newest evidence for tetrahydrocannabinol: cannabidiol oromucosal spray from randomized clinical trials. Neurodegenerative disease management, 9(2s), 9-13. |
|
Penner, I. K., & Hartung, H. P. (2019). The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. Brain, 142(9), 2552-2555. |
|
Amato, L., Davoli, M., Minozzi, S., Mitrova, Z., Parmelli, E., Saulle, R., & Vecchi, S. (2016). Systematic reviews on therapeutic efficacy and safety of Cannabis (including extracts and tinctures) for patients with multiple sclerosis, chronic neuropathic pain, dementia and Tourette syndrome, HIV/AIDS, and cancer receiving chemotherapy. Roma, Italy: Department of Epidemiology Lazio Regional Health Service. |
|
Haupts, M., Vila, C., Jonas, A., Witte, K., & Alvarez-Ossorio, L. (2016). Influence of previous failed antispasticity therapy on the efficacy and tolerability of THC: CBD oromucosal spray for multiple sclerosis spasticity. European neurology, 75(5-6), 236-243. |
|
Hall, W. (2015). Focus: Addiction: US Policy Responses to Calls for the Medical Use of Cannabis. The Yale journal of biology and medicine, 88(3), 257. |
|
Ueberall, M. A., Essner, U., & Mueller-Schwefe, G. H. (2019). Effectiveness and tolerability of THC: CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. Journal of pain research, 12, 1577. |
|
Meuth, S. G., Vila, C., & Dechant, K. L. (2015). Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert review of neurotherapeutics, 15(8), 909-918. |
|
Etges, T., Karolia, K., Grint, T., Taylor, A., Lauder, H., Daka, B., & Wright, S. (2016). An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex®(THC: CBD, nabiximols) oromucosal spray. Therapeutics and Clinical Risk Management, 12, 1667. |
|
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017). Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. Multiple sclerosis and related disorders, 17, 22-31. |
|
Zettl, U. K., Rommer, P., Hipp, P., & Patejdl, R. (2016). Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic advances in neurological disorders, 9(1), 9-30. |
|
Keating, G. M. (2017). Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex®): a review in multiple sclerosis-related spasticity. Drugs, 77(5), 563. |
|
Nischala, T. (2016). Multiple sclerosis patients gets the most help from Nurses. J Nurs Health Sci| Volume, 2(3). |
|
Nischala, T. (2016). Multiple sclerosis patients gets the most help from Nurses. J Nurs Health Sci| Volume, 2(3). |
|
Dobryakova, E., Rocca, M. A., & Filippi, M. (2018). Cerebral reorganization and cognition in multiple sclerosis. |
|
